These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1501395)

  • 1. [Biological response modifiers and urological cancer].
    Ohmori H; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1992 Jun; 83(6):850-6. PubMed ID: 1501395
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive cellular therapy of urological neoplastic disease.
    Gold JE; Osband ME; Krane RJ
    Cancer Treat Rev; 1994 Apr; 20(2):173-90. PubMed ID: 8156540
    [No Abstract]   [Full Text] [Related]  

  • 3. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
    Wirth M
    Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 5. Present status of cancer treatment in Singapore-management of urological cancers.
    Tun KH; Tan EC; Foo KT
    Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1139-45. PubMed ID: 1514826
    [No Abstract]   [Full Text] [Related]  

  • 6. Adoptive cellular therapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1991; 12():213-30. PubMed ID: 1931444
    [No Abstract]   [Full Text] [Related]  

  • 7. [Intra-arterial chemotherapy in urological cancer].
    Mitsumori K; Sato K; Kato T
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):197-203. PubMed ID: 11865624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 9. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 10. Adoptive cellular therapy.
    Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
    Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of immunotherapy for urological tumours.
    Hrouda D; Muir GH; Dalgleish AG
    Br J Urol; 1997 Mar; 79(3):307-16. PubMed ID: 9117206
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cell therapy in renal cell carcinoma].
    Ravaud A
    Bull Cancer; 2003; 90(8-9):711-21. PubMed ID: 14609761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cell carcinoma: recent progress and future directions.
    Mulders P; Figlin R; deKernion JB; Wiltrout R; Linehan M; Parkinson D; deWolf W; Belldegrun A
    Cancer Res; 1997 Nov; 57(22):5189-95. PubMed ID: 9371523
    [No Abstract]   [Full Text] [Related]  

  • 15. [Update on the medical treatment of urologic tumors].
    Culine S
    Bull Cancer; 2000 Jan; 87(1):71-5. PubMed ID: 10673634
    [No Abstract]   [Full Text] [Related]  

  • 16. Bibliography. Current world literature. Renal and urological problems.
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):218-38. PubMed ID: 18685367
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Response criteria for urological cancer treatment].
    Nihon Hinyokika Gakkai Zasshi; 1992 Apr; 83(4):447-72. PubMed ID: 1593826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.